LAWRENCEVILLE, N.J., Oct. 23, 2025 (GLOBE NEWSWIRE) -- IMUNON (IMNN), Inc. (Nasdaq: IMNN), a clinical-stage company in Phase 3 development with its DNA-mediated immunotherapy, today announced that new ...
Highly encouraging overall survival data from the Phase 2 OVATION 2 Study of IMNN-001 has been accepted for oral presentation at the prestigious ASCO Annual Meeting, indicating strong interest in the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results